Kodiak Sciences Inc. (KOD)
D
Pipeline Grade
Financial Position (from SEC Filings)
$169.5M
Cash & Equivalents
$40.0M
Quarterly Burn Rate
13 mo
Est. Cash Runway
$2,585M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase3 Readout | — |
| 2027-02-01 | Phase3 Readout | — |
| 2027-04-01 | Phase3 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06990399 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary... | PHASE3 | Recruiting | 600 |
| NCT06556368 | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Pa... | PHASE3 | Active Not Recruiting | 675 |
| NCT06996080 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary... | PHASE3 | Recruiting | 300 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.